X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Europe

Cordis Corporation Manufacturing Plant, Cashel, Co Tipperary, Ireland

Yuvraj_pawp by Yuvraj_pawp
6th September 2014
in Europe, Projects

Cordis Corporation was established in Miami in Florida, US in 1959. The company is a subsidiary of the pharmaceutical major Johnson & Johnson, producing medical device products (drug-eluting stents) for patients suffering from coronary artery disease and a variety of other vascular disorders.

In July 2006 Cordis, in conjunction with Johnson & Johnson, decided to make a €100m investment to secure the future of production in Ireland and create a new complement of 460 jobs over a three-year period.

“The 180,000ft² plant at Cashel in County Tipperary, which combined functions of manufacturing and development, was built on a 40-acre site.”

This included 400 people in manufacturing and 60 additional positions at the finished goods testing centre and at the development laboratory.

The 180,000ft² plant at Cashel in County Tipperary, which combined the functions of manufacturing and development, was built on a 40-acre site adjacent to Alza (another subsidiary of Johnson & Johnson) and a producer of drug delivery systems.

Alza was built in 2001 and is a large-scale manufacturer of products incorporating D-TRANS transdermal technology, such as NicoDerm CQ and Durogesic.

Cordis at Cashel provided the entire production of drug eluting stents for Johnson & Johnson in all markets outside of the US. Alza and Cordis share some common infrastructure and facilities on the site, such as quality control and manufacturing services.

The plant, the sixth for Johnson & Johnson in Ireland, became operational in the first quarter of 2008. The investment was supported by the Irish Development Agency (IDA).

In June 2011, Johnson & Johnson announced the closure of the Cashel plant. The decision was part of a restructuring programme aimed towards cutting 1,000 jobs worldwide. The closure was also due to Cordis’ decision to cease manufacturing of its CYPHER drug-eluting stents.

Cordis Corporation and its pharmaceutical products

 

Cordis is one of the world leaders in producing drug-eluting stents (DES), which offer an effective alternative to open-heart surgery.

A drug-eluting stent is a coronary stent that can loosely be described as a supporting scaffold, which is placed into narrowed and diseased coronary arteries and slowly releases a specialised drug that will slow and prevent cell proliferation.

The use of the drug-eluting variety of stent prevents the process of fibrosis that, alongside clots formation, could block the stented artery (restenosis). The stent is usually placed in the coronary artery by an interventional cardiologist during an angioplasty procedure, which is preferable to full-blown open-heart surgery.

DES use is now much more preferable to bare metal stents because they have a higher success rate and much lower rates of subsequent major adverse cardiac events (MACE).

Stent and drug combinations

 

The Cashel facility used the latest state-of-the-art technologies for stent manufacture and developed future drug-device combinations in the field of interventional cardiology, with major process and product development capabilities. The facility includes an 180,000ft² production building along with a development laboratory and a finished goods testing facility.

The facilities supported demand for the CYPHER family of drug-eluting stents (launched in 2003), including the CYPHER Sirolimus-eluting Coronary Stent and the CYPHER SELECT Plus Sirolimus-eluting Coronary Stent.

The latter received the CE mark in June 2006 and became available outside the US in the third quarter of 2006.

Extended facilities at Cordis’ Cashel site

 

Following the opening of the Cordis facility at the start of 2008, an extension project was launched.

“Cordis is one of the world leaders in producing drug-eluting stents (DES), which offer an effective alternative to open-heart surgery.”

The project involved construction of a new quality control laboratory and an extension to the canteen at the site (the work was carried out near the cleanroom facilities).

Work included demolition and extension of the existing canteen and office space and construction of a new quality control laboratory and associated infrastructure.

The work on the canteen was carried out in three phases, two construction phases and a final demolition of the existing canteen to allow continued use of facilities during the construction phase.

The laboratory was a single-storey steel and concrete construction with a suspended concrete on metal deck roof to allow for a possible first floor in the future. The architect / engineer for the €5.7m project was PM Group and the builder and civil engineer was L & M Keating. This project was completed by December 2008.

Cordis’ manufacturing and development site in Cashel produced drug-eluting stents.
Drug-eluting stents contain drugs that prevent cell proliferation, allowing their long-term use.
The Cordis facility also hosted the development of the next generation of stent-type devices.
Drug-eluting stent placement in angioplasty procedures is preferable to open-heart surgery.
Cordis is one of the world’s leading producers of drug-eluting stents.

Tags: Europe
Previous Post

Bidachem Active Pharmaceutical Ingredients Plant, Bergamo, Italy

Next Post

GlaxoSmithKline Vaccine Manufacturing Plant, St-Amand-Les-Eaux, France

Related Posts

Dr Reddy's Lab gets DCGI nod for Sputnik Phase 2 & 3 trials
Europe

RDIF and Minapharm Agree to Produce over 40 Million Doses of the Sputnik V Vaccine in Egypt

26th April 2021
Sputnik V: World's First COVID-19 Vaccine Now Available to Public in Russia
Europe

Sputnik V: World’s First COVID-19 Vaccine Now Available to Public in Russia

26th September 2020
AstraZeneca agrees to supply Europe with 400 million doses of COVID-19 vaccine
Europe

Valneva Announces Major COVID-19 Vaccine Partnership with U.K. Government

21st September 2020
Gilead's drug remdesivir gets US FDA's emergency use authorisation for COVID-19
Europe

Gilead’s drug remdesivir gets US FDA’s emergency use authorisation for COVID-19

4th May 2020
Europe

Pharmintech 2019: Big increase in International Participation Expected

18th November 2018
Europe

Novo Nordisk acquires Ziylo Ltd to accelerate its development of glucose responsive insulins

17th August 2018
Next Post

GlaxoSmithKline Vaccine Manufacturing Plant, St-Amand-Les-Eaux, France

Latest News

Global Biopharmaceutical Bioseparation Market Eyeing $20bn
Manufacturing

Global Biopharmaceutical Bioseparation Market Eyeing $20bn

4th July 2022
FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters
Manufacturing

FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters

4th July 2022
COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters
Manufacturing

COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters

4th July 2022
Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma
Manufacturing

AstraZeneca Cites Early Lung Cancer Immunotherapy Success

4th July 2022
FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In